Galapagos Current Ratio 2013-2021 | GLPG

Galapagos current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Galapagos Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $6.18B $0.70B 8.89
2021-03-31 $6.40B $0.73B 8.77
2020-12-31 $6.13B $0.73B 8.45
2020-09-30 $6.39B $0.70B 9.08
2020-06-30 $6.19B $0.68B 9.09
2020-03-31 $6.38B $0.69B 9.28
2019-12-31 $6.57B $0.64B 10.26
2019-09-30 $6.28B $0.70B 8.95
2019-06-30 $1.36B $0.21B 6.40
2019-03-31 $1.43B $0.23B 6.31
2018-12-31 $1.57B $0.26B 6.04
2018-09-30 $1.62B $0.31B 5.17
2018-06-30 $1.32B $0.29B 4.49
2018-03-31 $1.40B $0.28B 5.08
2017-09-30 $1.46B $0.18B 8.05
2017-03-31 $1.10B $0.14B 7.75
2016-03-31 $1.11B $0.12B 9.62
2015-12-31 $0.42B $0.08B 5.17
2015-09-30 $0.44B $0.04B 10.67
2015-06-30 $0.47B $0.05B 10.48
2015-03-31 $0.00B 0.00
2014-12-31 $0.28B $0.08B 3.54
2014-06-30 $0.35B $0.10B 3.36
2013-12-31 $0.24B $0.15B 1.57
2012-12-31 $0.17B $0.14B 1.22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.337B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76